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SUPPLEMENTARY NOTES
Genetic instability is a hallmark of tumor development. Mechanisms for maintenance of genomic stability are heterogeneous and identification of the genes responsible a critical goal of cancer biologists. The very large number of genetic alterations in breast tumors and genetic heterogeneity, even within a single breast tumor, strongly suggests that some mutator mechanism must be involved in breast tumorigenesis. Our hypothesis is that a mutator mechanism contributes to the development of breast cancer. However, since breast tumors do not display an obvious phenotype that signals the presence of a mutator defect (such is miCrosatellite instability), another scheme to identify defects in repair genes and their targets is necessary. Thus, our first objectiveis to use a novel yeast model system to identify genes that are previously unrecognized targets of mutator mechanisms and to determine whether these genes are altered in breast tumors. Our second objective is to identify genes that function as novel mutators in the yeast system then evaluate whether any are altered in breast tumors. The identification of mutator genes and their targets that contribute to the etiology of breast cancer will enhance our understanding of the genetic mechanisms involved in initiation and progress of disease. These genes will impact drug and biomarker discovery and ultimately, revolutionize patient care. [2] . However, the very large number of genetic alterations in breast tumors, and genetic heterogeneity even within a single breast tumor, strongly suggest that other, as yet, unidentified repair genes must play a role in breast tumorigenesis.
Our proposal assumed that loss of function mutations in mutator genes contribute to the genetic heterogeneity observed in breast tumors. However, since breast tumors do not display a convenient phenotype (such as microsatellite instability) to signal the presence of repair defects, another scheme to identify mutator genes, and their targets, was necessary. Thus, we designed a straight forward, yeast-based screen to identify these two classes of genes. Our rationale for this project was based on the evolutionary conservation between DNA repair systems in yeast and humans. This conservation enabled us to detect and measure, in yeast strains, increases in mutation rates in human tumor suppressor genes due to defects in known mismatch repair genes [3] .
Our research plan consisted of two objectives. First, we proposed to use a novel yeast-based screen to identify genes that are previously unrecognized targets of mutator mechanisms. Second, we proposed to use the same yeast-based screen to identify genes that function novel mutators. Our aims included generating a high quality, complex breast cDNA library, using this library in a screen designed to identify genes that are targets of mutators, screening for novel mutator genes using known tumor suppressor genes as targets, and finally, analyzing both target and mutator genes in high-risk breast cancer families and in sporadic tumors.
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Body:
This progress report details all research objectives and progress made to date with an emphasis on progress made during the past year. In addition, we include a comprehensive report of all preliminary data (all data remains preliminary at this time) and research findings for this reporting period (Annual 02).
Statement of Work for DAMD17-02-1-0615 as actually funded.
Technical objective 1: Construction of a high quality breast cDNA library
Months 1-6: Culture normal breast mammary epithelial cells from dissected breast reduction material from premenopausal women. Confirm quality of cultures using immunohistochemical methods. Isolate total RNA, generate poly A+ RNA and convert to cDNA using standard techniques. Clone material into lambda TripLEX.
Transduce lambda TripLEX pahgemid library into E. coli BNN123 and isolate plasmid DNA.
Studies and Results, June 01, 2002-June 30, 2003
We proposed to construct a high quality normal breast cDNA library using reduction material from 3-4 premenopausal women. Normal mammary epithelial cells have been cultured, the quality of the cultures has been confirmed, and poly A+ RNA has been isolated.
Our rationale for pooling cDNA from different premenopausal women was to normalize the library for genetic contributions that are unique to a particular individual. However, in reviewing our rationale for constructing the breast library solely with cDNA from premenopausal women, we realized that the library should be 'complex' meaning that it should also consist of cDNA from normal epithelial cells from premenopausal women (as proposed),
and from postmenopausal women and breast tumors. Thus, construction of such a complex breast cDNA library would allow us to perform a more complete screen. We delayed pursuing this aim over the past year for the following reasons: First, we became aware of two publications that described screens for novel mutator genes [4, 5] . These reports directly impact year three of our proposal. The manuscripts describe the identification of novel mutator genes using approaches that are similar, although not identical, to our approach (See technical objective 6 of this proposal). Because others were already publishing their results, we felt that we needed to begin working on this objective immediately. Hence, most of our research for year two of this proposal (technical objectives 3-5) was postponed until year three.
As reported below, research during year two has focused on technical objective 6. Because preliminary work on this objective proved to be highly successful with, we believe, a greater potential to impact breast cancer, we continue to pursue this objective. We expect to complete technical objectives 6 and 7 early in year three. Thus, the focus of year three will be the completion of technical objectives 3-4. To our knowledge, no one has performed the type of screen we propose in objectives 3-5. Thus, we felt that delaying objectives 3-5 for a year while pursuing objectives 6 and 7 was worth the risk.
Technical objective 4: Identification of target genes and mutations and confirmation of hypermutabilit in candidate genes
Studies These clones were pooled independently so as to not bias the collection.
Control (parental)]
Figure 1
We have optimized our yeast transformation protocol. This modified, high efficiency protocol was used to transform the pools with plasmid pHJ3. Transformed clones were identified by growth on the appropriate selection media. For each pool, 3000 independent transformants were picked and gridded into 96 well plates. Clones were 9 then replica plated onto media to allow for mutation events to occur. After three days, clones were replica plated onto FOA media to identify FOAR strains. Strains capable of enhanced growth on FOA due to an acquired mutation in the plasmid target sequence were identified and scored (Figure 1 ).
Transformants were scored on a scale of 0 to +4 with 0 representing 0-5 colonies per patch, +1 representing 6-12 colonies, +2 represents 13-19 colonies, +3 representing 19-25 colonies, and +4 representing more than 25 colonies or confluent growth. As a control, the parental strain (which does not contain a deletion in any open reading frame) was transformed and carried through the screen (Figure 1) . Transformants of the parental strain that grew on FOA media reflect the background mutation rate of the strain. Scoring results for pool A transformants are shown in the following In the first round of the screen, 396 strains were scored +2 or greater, with the majority of strains scored as 0.
Interestingly, these results are consist with those reported in a similar screen [4] . All 159 clones with a growth score of +4 were re-analyzed on FOA media to determine if the clones continued to display a mutator phenotype. Of these, approximately half (3.6% of all clones analyzed) appeared to be true mutators. Sequence analysis of these clones revealed a number of interesting candidate genes including those involved in signal transduction, sister chromatid segregation, cytokinesis, sumoylation, neddylation, protein synthesis and transport. Candidate mutators are listed in the following table: We are currently in the process of determining mutation rates for all candidate mutators. Those that consistently display a mutation rate above background will be analyzed in sporadic breast tumors as outline in objective 7.
interesting candidate genes. These genes will be evaluated in sporadic breast tumors and in high risk breast cancer families to determine if they play a role in development of inherited and/or sporadicdisease.
* We have continued to expand our breast tissue bank. To date, our bank consists of over 400 matched breast thmor and normal tissue samples.
Reportable Outcomes:
We report here the progress of the first and second year of a three-year award. All results remain.preliminary thus we have no reportable outcomes. Given that the screen for novel mutator genes will be completed imminently, we expect to submit a manuscript describing this work in the fall of 2004. We also anticipate completion of our screen for novel targets of mutators to be completed early in 2005 and thus expect to submit a manuscript describing that work in the spring of 2005.
Conclusions:
Tumor development is the result of an imbalance between mechanisms controlling gene regulation and genomic stability. Genomic stability is under genetic control. Thus, identification of genes that maintain stability is a goal of cancer biologists. Because a mutator mechanism contributes to the development of breast cancer, we have initiated research designed to identify heretofore, unrecognized targets of mutator mechanisms as well as novel mutators and to determine whether these genes are altered in breast tumors.
The scope of our research includes the evaluation of newly identified genes to determine whether any are altered in breast tumors. Discovery and functional assessment of these genes is essential for understanding the biology of breast cancer and for clinical applications, including identification of therapeutic targets, early breast cancer detection and improved prediction of breast cancer risk and disease course. If we discover novel targets of mutators and/or novel mutators with consequences for breast tumor development, we will open new pathways for investigation into detection and treatment of breast cancer. 13
